Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the rate and extent of absorption of Purepac, a
subsidiary of Alpharma Inc., U.S.A., galantamine and Janssen Pharmaceutica Products, L.P.,
U.S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fed conditions.